Logo image of AMAM

NEW AMBRX BIOPHARMA INC (AMAM) Stock Analyst Ratings

USA - Nasdaq - NASDAQ:AMAM - US6418711080 - Common Stock

28 USD
+0.02 (+0.07%)
Last: 3/6/2024, 8:00:01 PM
28 USD
0 (0%)
After Hours: 3/6/2024, 8:00:01 PM
Buy % Consensus

76

ChartMill assigns a Buy % Consensus number of 76% to AMAM. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 29.07. This target is 3.82% above the current price.
AMAM was analyzed by 14 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about AMAM.
In the previous month the buy percentage consensus was at a similar level.
AMAM was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.

Related screens

AMAM Historical Analyst RatingsAMAM Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -31 -28 -25 -22 -19 -16 -13 -10 -7 -4 -1 5 10

Price Target & Forecast

Price Low Median Mean High 28.0028.2828.5629.0731.50 - 1.00% 2.00% 3.82% 12.50%

Related screens

AMAM Current Analyst RatingAMAM Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5
Up and Down Grades
Date Firm Action Rating
2024-01-16 Baird Downgrade Outperform -> Neutral
2024-01-10 JMP Securities Downgrade Market Outperform -> Market Perform
2024-01-09 B. Riley Securities Downgrade Buy -> Neutral
2023-11-29 JMP Securities Reiterate Market Outperform -> Market Outperform
2023-11-20 JMP Securities Reiterate Market Outperform -> Market Outperform
2023-11-15 Goldman Sachs Maintains Neutral -> Neutral
2023-11-14 RBC Capital Maintains Outperform -> Outperform
2023-10-23 Cantor Fitzgerald Reiterate Overweight -> Overweight
2023-10-23 RBC Capital Maintains Outperform -> Outperform
2023-09-25 JMP Securities Initiate Market Outperform
2023-09-18 Cantor Fitzgerald Reiterate Overweight -> Overweight
2023-09-13 Goldman Sachs Maintains Neutral -> Neutral
2023-09-12 BTIG Initiate Buy
2023-08-16 Cantor Fitzgerald Reiterate Overweight -> Overweight
2023-07-31 RBC Capital Initiate Outperform
2023-06-14 B. Riley Securities Initiate Buy
2023-06-02 Oppenheimer Initiate Outperform
2023-05-19 Cantor Fitzgerald Initiate Overweight
2023-04-05 Baird Maintains Outperform
2023-02-28 Goldman Sachs Maintains Neutral
2023-02-27 Goldman Sachs Maintains Neutral
2022-05-24 Goldman Sachs Maintains Neutral
2022-04-07 Baird Initiate Outperform
2022-02-28 Goldman Sachs Initiate Neutral
2021-07-13 Cowen & Co. Initiate Outperform
2021-07-13 Goldman Sachs Initiate Buy
2021-07-13 B of A Securities Initiate Buy

NEW AMBRX BIOPHARMA INC / AMAM FAQ

What is the average price target for NEW AMBRX BIOPHARMA INC (AMAM) stock?

14 analysts have analysed AMAM and the average price target is 29.07 USD. This implies a price increase of 3.82% is expected in the next year compared to the current price of 28.


What is the consensus rating for NEW AMBRX BIOPHARMA INC (AMAM) stock?

The consensus rating for NEW AMBRX BIOPHARMA INC (AMAM) is 75.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.


What is the number of analysts for AMAM stock?

The number of analysts covering NEW AMBRX BIOPHARMA INC (AMAM) is 14.